[Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals

Wataru Akahata of VLP Therapeutics Japan and colleagues posted on September 6 a preprint* “Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals” on medRxiv, a preprint server for health sciences.

*Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (source).

• See the preprint abstract (full text also available): https://www.medrxiv.org/content/10.1101/2023.09.04.23294493v1